We rank companies based on fund manager, research analyst and news sentiment
XAIR stock icon

Beyond Air


About: Beyond Air Inc is a clinical-stage medical device and biopharmaceutical company that develops a Nitric Oxide (NO) Generator and Delivery System that uses NO generated from ambient air and delivers precise amounts of NO to the lungs for the potential treatment of respiratory and other diseases. The firm is applying its therapeutic expertise to develop treatments for pulmonary hypertension, in addition to treatments for lower respiratory tract infections.

Employees: 98

Funds holding %
of 6,474 funds
Analysts bullish %
News positive %

Fund manager confidence

Based on 2023 Q4 SEC filings by fund managers ($100M+ AUM)

41% more call options, than puts

Call options by funds: $116K | Put options by funds: $82.7K

25% more first-time investments, than exits

New positions opened: 10 | Existing positions closed: 8

18% more repeat investments, than reductions

Existing positions increased: 20 | Existing positions reduced: 17

3% more funds holding

Funds holding: 62 [Q3] → 64 (+2) [Q4]

0.3% more ownership

Funds ownership: 29.27% [Q3] → 29.56% (+0.3%) [Q4]

14% less capital invested

Capital invested by funds: $21.6M [Q3] → $18.5M (-$3.06M) [Q4]

Research analyst outlook

1 Wall Street Analyst provided 1 year price forecasts over the past 6 months

Low target
Avg. target
High target

1 analyst rating

Truist Securities
Gregory Fraser
14 Nov 2023

Financial journalist opinion

1 month ago
Beyond Air® Announces Pricing of $16.0 Million Registered Direct Offering of Common Stock and Warrants
GARDEN CITY, N.Y., March 20, 2024 (GLOBE NEWSWIRE) -- Beyond Air, Inc. (NASDAQ: XAIR) (“Beyond Air” or the “Company”), a commercial stage medical device and biopharmaceutical company focused on harnessing the power of endogenous and exogenous nitric oxide (NO) to improve the lives of patients suffering from respiratory illnesses, neurological disorders and solid tumors (through its affiliate Beyond Cancer, Ltd. (“Beyond Cancer”)), today announced that it has entered into a securities purchase agreement with healthcare focused institutional investors and accredited investors, including certain directors and officers of the Company, whereby the investors have agreed to purchase 9,638,556 shares of the Company's common stock and warrants to purchase up to an aggregate of 9,638,556 shares of common stock at a purchase price of $1.66 per share and accompanying warrant in a registered direct offering priced at-the-market under Nasdaq rules. The warrants have an exercise price of $2.25 per share, will be exercisable immediately upon issuance and will have a term of three years following the date of issuance. The Company can call the warrants if it reports equal to or greater than $4.5 million of net sales for the quarter ending March 31, 2025 which will require exercise within 10 business days. The closing of the offering is expected to occur on or about March 22, 2024, subject to the satisfaction of customary closing conditions.
Beyond Air® Announces Pricing of $16.0 Million Registered Direct Offering of Common Stock and Warrants